Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2024-12-12 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2024 first extraordinary general meeting of shareholders of Beijing SL Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting procedural information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2237 characters) and it is not a report publication announcement but the actual voting results announcement. Therefore, the correct classification is DVA with high confidence.
2024-12-12 Chinese
北京双鹭药业股份有限公司关于董事辞职及补选第九届董事会非独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director and the nomination of a new director to the board. It details the resignation of Mr. Wang Wenxin and the nomination of Mr. Zhang Jiaqi as a non-independent director, including compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of Board/Management Information, as it concerns changes in the company's board of directors.
2024-11-21 Chinese
北京双鹭药业股份有限公司拟续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (auditor) for the upcoming fiscal year 2024. It details the auditor's qualifications, independence, audit fees, and the approval process by the board and audit committee. It does not contain any actual financial statements or audit results, nor does it present a full audit report. The document is relatively short (2814 characters) and serves as a formal notice of the intention to reappoint the auditor, pending shareholder approval. Therefore, it is not an Audit Report (AR) itself but an announcement related to audit firm appointment. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-11-21 Chinese
第九届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifth meeting of the ninth Supervisory Board of Beijing Shuanglu Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and the approval of two key proposals: the reappointment of the audit firm for the 2024 fiscal year and the application for a comprehensive credit line from a bank. The document is an official disclosure of board-level decisions rather than a full audit report or financial statement. It does not contain detailed financial data or audit results but rather announces governance and financing-related decisions. Given the content focuses on supervisory board resolutions and approvals, it fits best under Board/Management Information (MANG). The document length is short (1069 characters), and it is not merely an announcement of a report publication but a substantive meeting resolution announcement. Therefore, the classification is MANG with high confidence.
2024-11-21 Chinese
第九届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth meeting of the ninth board of directors of Beijing Shuanglu Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on several proposals such as the reappointment of the audit firm, nomination of a new director, application for a credit facility, and the scheduling of an extraordinary general meeting. The content focuses on board decisions and changes in board membership rather than presenting financial statements or audit reports themselves. The document length is relatively short (2143 characters) and it serves as an official announcement of board meeting resolutions. Therefore, it fits best under the category of Board/Management Information (MANG).
2024-11-21 Chinese
北京双鹭药业股份有限公司关于召开2024年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting (临时股东大会) of Beijing Shuanglu Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, agenda items (such as reappointing the audit firm and electing a director), registration details, and proxy forms. There is no financial data or report content; rather, it is an announcement informing shareholders about the meeting and how to participate and vote. The document length is under 5,000 characters and it does not contain any financial statements or management discussion. Therefore, it is not an Annual Report, Interim Report, or Earnings Release. It is not a voting result declaration either, as it is a notice before the meeting. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-11-21 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.